awmsg logo



raltegravir (Isentress®)


Reference No. 593

Publication date:
12/08/2010


Appraisal information

raltegravir (Isentress®) 400 mg film-coated tablet


Company: Merck Sharp & Dohme Ltd
BNF category: Infections
NMG meeting date: 19/05/2010
AWMSG meeting date: 23/06/2010
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1110
Ministerial ratification: 03/08/2010

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Raltegravir (Isentress®) is recommended in combination with other antiretroviral medicinal products as an option for restricted use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients in accordance with British HIV Association (BHIVA) guidance. Raltegravir (Isentress®) should be restricted for use in patients who are resistant or intolerant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) or for whom these options are compromised due to drug-drug interactions. Current AWMSG advice, No 1808, in relation to the use of raltegravir (Isentress®) in treatment-experienced adult patients with human immunodeficiency virus (HIV-1) infection remains unchanged. AWMSG is of the opinion that raltegravir (Isentress®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download